pancreatic cancer

[Cell Death Discovery] Scientists probed molecular regulatory mechanism of KLF4 in malignant progression of pancreatic cancer.

[Carcinogenesis] Researchers demonstrated that perfluorooctanoic acid induced oxidative stress and focal ductal hyperplasia in the mouse pancreas.

[Oncogene] 6-aminopicolamine (6AP) acted as a water-soluble prodrug that was converted into intracellular bioactive metabolites that inhibited phosphogluconate dehydrogenase in vitro, and 6AP monotherapy demonstrated anti-metastatic efficacy with minimal toxicity in vivo.

[Zai Lab Limited] Zai Lab Limited announced treatment of the first patient in Greater China in the PANOVA-3 trial, a Phase III pivotal trial of Tumor Treating Fields in patients with pancreatic cancer.

[Fate Therapeutics, Inc.] Fate Therapeutics, Inc. announced that the US FDA has cleared the company’s Investigational New Drug application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor NK cell product candidate.

[Rafael Pharmaceuticals, Inc. (Globe Newswire, Inc.)] Rafael Pharmaceuticals, Inc. announced the completion of the first cohort of dose escalation with no DLT in the APOLLO 613 Phase I/II clinical trial of devimistat in combination with hydroxychloroquine in patients with relapsed clear cell sarcoma.